Abstract
The US Food and Drug Administration (FDA) created the accelerated approval pathway in 1992 to speed approval of drugs for serious diseases on the basis of surrogate end points “reasonably likely to predict clinical benefit.”1 The use of accelerated approval has increased over the past years, particularly for cancer drugs.2 In 2020, 53% of cancer drugs were approved by the FDA through accelerated approval.3 The comparable pathway in the European Union (EU) is conditional marketing authorization, which was implemented in 2006.4 The European Medicines Agency (EMA) only grants conditional marketing authorization to first (and not supplemental) indications.5 Another notable difference is the time limitation of conditional marketing authorization, which must be renewed annually with an application and interim report on outstanding study obligations.5

This publication has 13 references indexed in Scilit: